Valeant price target lowered to $167 from $209 at Cantor Cantor cut its price target on Valeant (VRX) after the comapny reported in-line Q2 results but lowered its 2014 guidance. The firm still expects Valeant to acquire Allergan (AGN), and the firm notes that it has not included Allergan in its Valeant estimates. It keeps a Buy rating on Valeant.
Valeant and Progenics' Relistor eceives positive opinion from EMA Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.